Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cosmo NV's Enterprise Value is CHF922.55 Mil.
Cosmo NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-19.45 Mil. Therefore, Cosmo NV's EV-to-OCF for today is -47.44.
The historical rank and industry rank for Cosmo NV's EV-to-OCF or its related term are showing as below:
XSWX:COPN'
s EV-to-OCF Range Over the Past 10 Years
Min: -180.66 Med: 12.86 Max: 103.83
Current: -47.44
During the past 13 years, the highest EV-to-OCF of Cosmo NV was 103.83. The lowest was -180.66. And the median was 12.86.
XSWX:COPN's EV-to-OCF is ranked better than 95.43% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.41
vs XSWX:COPN: -47.44
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cosmo NV's share price for today is CHF63.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-0.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cosmo NV EV-to-OCF Related Terms
Cosmo NV EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cosmo NV's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cosmo NV's EV-to-OCF falls into.
Cosmo NV's current Enterprise Value is CHF922.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-19.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (XSWX:COPN) has a EV-to-OCF of -47.44 as of Jul. 25, 2026. According to the industry distribution chart, Cosmo NV ranks #46 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Cosmo NV's EV-to-OCF too high?
Cosmo NV's current EV-to-OCF is -47.44. Based on the distribution chart, Cosmo NV ranks #46 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #46 out of 1007 companies for EV-to-OCF. This places Cosmo NV in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.41, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current EV-to-OCF is -47.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:COPN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.71, compared to a current price of CHF63.60 — trading 56.2% above its estimated fair value. The current EV-to-OCF is -47.44. Cosmo NV's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cosmo NV (XSWX:COPN), the current EV-to-OCF is -47.44 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:COPN) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF63.60 is trading 56.2% above its estimated GF Value™ of CHF40.71.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:COPN:
EV-to-OCF: -47.44
GF Value™: CHF40.71 vs. price of CHF63.60 (56.2% above fair value)
No single metric tells the full story. See the XSWX:COPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
78GF Score
Get the complete analysis for XSWX:COPN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:COPN has been successfully added to your 
